Tech Company Financing Transactions
CiVi Biopharma Funding Round
On 1/7/2017, CiVi Biopharma announced $40 million in Series A funding from Tavistock Life Sciences.
Transaction Overview
Company Name
Announced On
1/7/2017
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series A
Investors
Proceeds Purpose
The proceeds of the financing will be used primarily to fund the completion of pre-clinical and early phase I clinical development of CiVi Biopharma's LNA PCSK-9 drug, which the company recently licensed from F.Hoffmann-La Roche.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
5425 Wisconsin Ave. 6th Floor
Chevy Chase, MD 20815
USA
Chevy Chase, MD 20815
USA
Phone
Website
Email Address
Overview
CiVi Biopharma Inc. is a US-based, privately held biopharmaceutical company, founded in 2016. The company's research and development activities are focused on creating novel therapies against cardiovascular and metabolic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Shal Jacobovitz
Chief Scientific Officer
Henrik Ørum
VP - Bus. Development
Chuck Shear
Browse more venture capital transactions:
Prev: 1/7/2017: Cogito venture capital transaction
Next: 1/7/2017: Ittavi venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs